Cargando…

Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles

We previously designed a novel transdermal formulation containing ketoprofen solid nanoparticles (KET-NPs formulation), and showed that the skin penetration from the KET-NPs formulation was higher than that of a transdermal formulation containing ketoprofen microparticles (KET-MPs formulation). Howe...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagai, Noriaki, Ogata, Fumihiko, Ishii, Miyu, Fukuoka, Yuya, Otake, Hiroko, Nakazawa, Yosuke, Kawasaki, Naohito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073289/
https://www.ncbi.nlm.nih.gov/pubmed/30041452
http://dx.doi.org/10.3390/ijms19072138
_version_ 1783344157323952128
author Nagai, Noriaki
Ogata, Fumihiko
Ishii, Miyu
Fukuoka, Yuya
Otake, Hiroko
Nakazawa, Yosuke
Kawasaki, Naohito
author_facet Nagai, Noriaki
Ogata, Fumihiko
Ishii, Miyu
Fukuoka, Yuya
Otake, Hiroko
Nakazawa, Yosuke
Kawasaki, Naohito
author_sort Nagai, Noriaki
collection PubMed
description We previously designed a novel transdermal formulation containing ketoprofen solid nanoparticles (KET-NPs formulation), and showed that the skin penetration from the KET-NPs formulation was higher than that of a transdermal formulation containing ketoprofen microparticles (KET-MPs formulation). However, the precise mechanism for the skin penetration from the KET-NPs formulation was not clear. In this study we investigated whether energy-dependent endocytosis relates to the transdermal delivery from a 1.5% KET-NPs formulation. Transdermal formulations were prepared by a bead mill method using additives including methylcellulose and carbopol 934. The mean particle size of the ketoprofen nanoparticles was 98.3 nm. Four inhibitors of endocytosis dissolved in 0.5% DMSO (54 μM nystatin, a caveolae-mediated endocytosis inhibitor; 40 μM dynasore, a clathrin-mediated endocytosis inhibitor; 2 μM rottlerin, a macropinocytosis inhibitor; 10 μM cytochalasin D, a phagocytosis inhibitor) were used in this study. In the transdermal penetration study using a Franz diffusion cell, skin penetration through rat skin treated with cytochalasin D was similar to the control (DMSO) group. In contrast to the results for cytochalasin D, skin penetration from the KET-NPs formulation was significantly decreased by treatment with nystatin, dynasore or rottlerin with penetrated ketoprofen concentration-time curves (AUC) values 65%, 69% and 73% of control, respectively. Furthermore, multi-treatment with all three inhibitors (nystatin, dynasore and rottlerin) strongly suppressed the skin penetration from the KET-NPs formulation with an AUC value 13.4% that of the control. In conclusion, we found that caveolae-mediated endocytosis, clathrin-mediated endocytosis and macropinocytosis are all related to the skin penetration from the KET-NPs formulation. These findings provide significant information for the design of nanomedicines in transdermal formulations.
format Online
Article
Text
id pubmed-6073289
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-60732892018-08-13 Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles Nagai, Noriaki Ogata, Fumihiko Ishii, Miyu Fukuoka, Yuya Otake, Hiroko Nakazawa, Yosuke Kawasaki, Naohito Int J Mol Sci Article We previously designed a novel transdermal formulation containing ketoprofen solid nanoparticles (KET-NPs formulation), and showed that the skin penetration from the KET-NPs formulation was higher than that of a transdermal formulation containing ketoprofen microparticles (KET-MPs formulation). However, the precise mechanism for the skin penetration from the KET-NPs formulation was not clear. In this study we investigated whether energy-dependent endocytosis relates to the transdermal delivery from a 1.5% KET-NPs formulation. Transdermal formulations were prepared by a bead mill method using additives including methylcellulose and carbopol 934. The mean particle size of the ketoprofen nanoparticles was 98.3 nm. Four inhibitors of endocytosis dissolved in 0.5% DMSO (54 μM nystatin, a caveolae-mediated endocytosis inhibitor; 40 μM dynasore, a clathrin-mediated endocytosis inhibitor; 2 μM rottlerin, a macropinocytosis inhibitor; 10 μM cytochalasin D, a phagocytosis inhibitor) were used in this study. In the transdermal penetration study using a Franz diffusion cell, skin penetration through rat skin treated with cytochalasin D was similar to the control (DMSO) group. In contrast to the results for cytochalasin D, skin penetration from the KET-NPs formulation was significantly decreased by treatment with nystatin, dynasore or rottlerin with penetrated ketoprofen concentration-time curves (AUC) values 65%, 69% and 73% of control, respectively. Furthermore, multi-treatment with all three inhibitors (nystatin, dynasore and rottlerin) strongly suppressed the skin penetration from the KET-NPs formulation with an AUC value 13.4% that of the control. In conclusion, we found that caveolae-mediated endocytosis, clathrin-mediated endocytosis and macropinocytosis are all related to the skin penetration from the KET-NPs formulation. These findings provide significant information for the design of nanomedicines in transdermal formulations. MDPI 2018-07-23 /pmc/articles/PMC6073289/ /pubmed/30041452 http://dx.doi.org/10.3390/ijms19072138 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Nagai, Noriaki
Ogata, Fumihiko
Ishii, Miyu
Fukuoka, Yuya
Otake, Hiroko
Nakazawa, Yosuke
Kawasaki, Naohito
Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles
title Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles
title_full Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles
title_fullStr Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles
title_full_unstemmed Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles
title_short Involvement of Endocytosis in the Transdermal Penetration Mechanism of Ketoprofen Nanoparticles
title_sort involvement of endocytosis in the transdermal penetration mechanism of ketoprofen nanoparticles
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6073289/
https://www.ncbi.nlm.nih.gov/pubmed/30041452
http://dx.doi.org/10.3390/ijms19072138
work_keys_str_mv AT nagainoriaki involvementofendocytosisinthetransdermalpenetrationmechanismofketoprofennanoparticles
AT ogatafumihiko involvementofendocytosisinthetransdermalpenetrationmechanismofketoprofennanoparticles
AT ishiimiyu involvementofendocytosisinthetransdermalpenetrationmechanismofketoprofennanoparticles
AT fukuokayuya involvementofendocytosisinthetransdermalpenetrationmechanismofketoprofennanoparticles
AT otakehiroko involvementofendocytosisinthetransdermalpenetrationmechanismofketoprofennanoparticles
AT nakazawayosuke involvementofendocytosisinthetransdermalpenetrationmechanismofketoprofennanoparticles
AT kawasakinaohito involvementofendocytosisinthetransdermalpenetrationmechanismofketoprofennanoparticles